Black Diamond Therapeutics, Inc. Common Stock
Here’s whether Black Diamond Therapeutics, Inc. Common Stock (BDTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: 50-day MA is rising (+5.24% over 10 days); RSI 44 — healthy momentum range; strong 1-year return of +10.7%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 3-month momentum negative (-10.6%); rising volume on a downtrend (distribution, 1.78x avg). Currently 53.9% off its 52-week high. Score: -1/7.
BDTX is trading below its 200-day MA ($2.95) — a key warning sign the longer-term trend is under pressure. An RSI of 43.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +10.7% compares to +27.9% for SPY (trailed the market by 17.2%). The current 53.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.